NVO Jan 2026 110.000 put
| Previous close | 10.50 |
| Open | 10.50 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 110.00 |
| Expiry date | 2026-01-16 |
| Day's range | 10.50 - 10.50 |
| Contract range | N/A |
| Volume | |
| Open interest | 469 |
- Yahoo Finance Video
Novo Nordisk slides while Moderna pops: Tale of two pharma stocks
Pharmaceutical stocks Novo Nordisk (NVO) and Moderna (MRNA) are trending in opposite directions following their earnings reports. Despite topping Wall Street's profit expectations, Novo Nordisk shares are sinking as the company fell short of estimates for its popular GLP-1 weight-loss drug, Wegovy. Meanwhile, Moderna is on the rise even after reporting first quarter losses. Moderna's growth is largely due to an uptick in coronavirus boosters and an expansion into the Brazillian market. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Melanie Riehl
Yahoo FinanceNovo Nordisk sales up 26% driven by GLP-1s, misses 11% on Wegovy
Novo Nordisk CEO Lars Jørgensen tells Yahoo Finance the company is confident about a robust GLP-1 sales year despite missing Wall Street estimates.
ReutersUS FTC seeks more information on Novo Nordisk parent-Catalent deal
The deal was announced in February and Novo Nordisk Foundation has since refiled its application to the U.S. FTC seeking regulatory approval for it. Catalent in a regulatory filing on Friday said the companies were in the process of gathering information and documents to respond to FTC's request received on May 2 and intend to continue to cooperate with the regulator. Catalent and Novo Holdings expect to close the deal towards the end of calendar year 2024.
